Testing for blood-based DNA markers can help identify which colorectal patients face a higher risk of cancer recurrence of death, according to a study published Feb. 1 in Clinical Epigenetics.
The study was led by researchers from Tampa, Fla.-based Moffitt Cancer Center and focused on identifying which blood-based DNA markers — known as protein epiScores — were associated with worse outcomes among colorectal cancer patients.
Here are three things to know from the study:
- Researchers identified four protein epiScores strongly associated with worse outcomes among colorectal cancer patients. Patients with higher levels of those markers experienced a 60% to 70% greater risk of recurrence.
Higher levels of one marker, LGALS3BP, were associated with an 80% increased risk of death among colorectal cancer patients.
- When accounting for cancer stage and patient age, prediction accuracy based on the protein epiScores increased from 64% to 70% for cancer recurrence, and from 70% to 75% for overall survival.
- “While the approach requires validation in additional patient populations, the results demonstrate the potential of using a simple blood draw taken before treatment to refine risk assessment in colorectal cancer,” according to a Feb. 9 news release from Moffitt Cancer Center.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
